| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRCARDIO.2013.15 |
| P698 | PubMed publication ID | 23419899 |
| P50 | author | Valentín Fuster Carulla | Q977751 |
| P2093 | author name string | Michael C Kim | |
| Mark R Kahn | |||
| Michael J Robbins | |||
| P2860 | cites work | Cardiac testing for coronary artery disease in potential kidney transplant recipients | Q24204028 |
| Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report | Q27861020 | ||
| Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial | Q28194232 | ||
| Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery | Q28206536 | ||
| MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q28214393 | ||
| A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease | Q28238811 | ||
| Dabigatran versus warfarin in patients with atrial fibrillation | Q28256895 | ||
| Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial | Q28278243 | ||
| The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation | Q29614696 | ||
| Apixaban versus warfarin in patients with atrial fibrillation | Q29617563 | ||
| Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
| Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group | Q29619460 | ||
| Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial | Q32054903 | ||
| Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. | Q33414957 | ||
| Digitalis | Q33539598 | ||
| Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis | Q33611763 | ||
| Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. | Q45929238 | ||
| Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients | Q46063354 | ||
| Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis | Q46345823 | ||
| Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial | Q46464014 | ||
| Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach | Q46535487 | ||
| Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis | Q46610834 | ||
| The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial | Q46678652 | ||
| Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? | Q46799946 | ||
| Beneficial impact of spironolactone in diabetic nephropathy | Q46826573 | ||
| Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. | Q46833326 | ||
| Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial | Q46843183 | ||
| Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
| Impact of chronic renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary intervention with sirolimus-eluting stents versus bare metal stents | Q46975103 | ||
| Impact of drug-eluting stents on clinical and angiographic outcomes in dialysis patients | Q46981949 | ||
| Prognostic value of myocardial perfusion imaging in predicting outcome after renal transplantation | Q47760954 | ||
| Atrial fibrillation in incident dialysis patients | Q48587231 | ||
| Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? | Q50657801 | ||
| Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients. | Q51089536 | ||
| Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization | Q51136785 | ||
| Valve replacement surgery in end-stage renal failure: mechanical prostheses versus bioprostheses | Q51267181 | ||
| Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators | Q51403903 | ||
| Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures | Q51671505 | ||
| Coronary artery bypass surgery versus percutaneous coronary artery intervention in patients on chronic hemodialysis: does a drug-eluting stent have an impact on clinical outcome? | Q51830492 | ||
| A method of determining the dose of digoxin for heart failure in the modern era. | Q51926952 | ||
| Screening diabetic transplant candidates for coronary artery disease: identification of a low risk subgroup | Q52391463 | ||
| Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). | Q53150011 | ||
| Importance of venous congestion for worsening of renal function in advanced decompensated heart failure | Q33799478 | ||
| Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. | Q33882750 | ||
| Rosuvastatin and cardiovascular events in patients undergoing hemodialysis | Q34016806 | ||
| A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure | Q34106793 | ||
| Apixaban in Patients with Atrial Fibrillation | Q34163710 | ||
| Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction | Q34187441 | ||
| Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme | Q34246882 | ||
| Digoxin associates with mortality in ESRD. | Q34455390 | ||
| Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial | Q34456841 | ||
| Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators | Q34539986 | ||
| The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial | Q34630074 | ||
| Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study | Q34663424 | ||
| Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). | Q34682919 | ||
| ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Gui | Q34694837 | ||
| Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention | Q34726838 | ||
| Valve replacement in patients on chronic renal dialysis: implications for valve prosthesis selection | Q34740306 | ||
| C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients | Q34766550 | ||
| 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Commit | Q34838596 | ||
| A call to action: variability in guidelines for cardiac evaluation before renal transplantation | Q34927152 | ||
| Inflammation in end-stage renal disease: sources, consequences, and therapy | Q34928704 | ||
| Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon | Q34986029 | ||
| Rosuvastatin in diabetic hemodialysis patients | Q35108893 | ||
| Comparison of bare-metal and drug-eluting stents in patients with chronic kidney disease (from the NHLBI Dynamic Registry) | Q35549533 | ||
| Effect of pravastatin on cardiovascular events in people with chronic kidney disease | Q35886206 | ||
| Survival after coronary revascularization among patients with kidney disease | Q35903366 | ||
| Warfarin in atrial fibrillation patients with moderate chronic kidney disease | Q35985876 | ||
| Major bleeding in hemodialysis patients | Q36666958 | ||
| Mechanisms of vascular calcification in chronic kidney disease | Q37038200 | ||
| Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review | Q37063760 | ||
| Outcome of patients on renal replacement therapy after colorectal surgery | Q37089791 | ||
| Kidney function influences warfarin responsiveness and hemorrhagic complications | Q37146449 | ||
| Cardiorenal syndrome | Q37324890 | ||
| Dilemmas in the management of atrial fibrillation in chronic kidney disease | Q37353569 | ||
| Predictors of survival in patients with end-stage renal disease evaluated for kidney transplantation | Q53464892 | ||
| Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure | Q54152720 | ||
| Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. | Q54583949 | ||
| Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation | Q56620375 | ||
| Cardiovascular Mortality in Chronic Kidney Disease Patients Undergoing Percutaneous Coronary Intervention Is Mainly Related to Impaired P2Y12 Inhibition by Clopidogrel | Q56908098 | ||
| SHARP: a stab in the right direction in chronic kidney disease | Q57956754 | ||
| Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report | Q63694274 | ||
| Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? | Q64112079 | ||
| Calcific aortic stenosis: a complication of chronic uraemia | Q69481222 | ||
| Aortic and mitral valve calcification in patients with end-stage renal disease | Q69906950 | ||
| Clinical and echocardiographic disease in patients starting end-stage renal disease therapy | Q72192935 | ||
| Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators | Q72232746 | ||
| Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice | Q73048909 | ||
| Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group | Q73288580 | ||
| Accelerated progression of calcific aortic stenosis in dialysis patients | Q73621210 | ||
| Cardiac valve replacement in patients on dialysis: influence of prosthesis on survival | Q74255805 | ||
| The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial | Q74452235 | ||
| Prognostic value of dipyridamole thallium-201 screening to minimize perioperative cardiac complications in diabetics undergoing kidney or kidney-pancreas transplantation | Q74517248 | ||
| Poor Long-Term Survival after Acute Myocardial Infarction among Patients on Long-Term Dialysis | Q77300271 | ||
| Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis | Q77814884 | ||
| Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients | Q78171196 | ||
| Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis | Q79096322 | ||
| Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease | Q79226809 | ||
| Risks of coronary artery bypass surgery in dialysis-dependent patients--analysis of the 2001 National Inpatient Sample | Q79770924 | ||
| Rate of progression of valvular aortic stenosis in patients undergoing dialysis | Q79850251 | ||
| Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients | Q79870463 | ||
| Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens | Q80796915 | ||
| K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients | Q81607027 | ||
| Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease | Q81610662 | ||
| Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database | Q82141175 | ||
| Comparison of haemodialysis patients and non-haemodialysis patients with respect to clinical characteristics and 3-year clinical outcomes after sirolimus-eluting stent implantation: insights from the Japan multi-centre post-marketing surveillance re | Q83084037 | ||
| Chronic Kidney Disease and CHADS2 Score Independently Predict Cardiovascular Events and Mortality in Patients With Nonvalvular Atrial Fibrillation | Q83236890 | ||
| Coronary artery bypass surgery is superior to percutaneous coronary intervention with drug-eluting stents for patients with chronic renal failure on hemodialysis | Q84282493 | ||
| Diminished benefits of drug-eluting stents versus bare metal stents in patients with severe renal insufficiency | Q84388659 | ||
| Impact of renal insufficiency on safety and efficacy of drug-eluting stents compared to bare-metal stents at 6 years | Q84514601 | ||
| Cardiovascular risk factors in patients with chronic kidney disease | Q37557361 | ||
| Cardiorenal syndrome: new perspectives | Q37765094 | ||
| Warfarin in haemodialysis patients with atrial fibrillation: what benefit? | Q37806450 | ||
| Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter | Q37844248 | ||
| Sudden Cardiac Death in Hemodialysis Patients: An In-Depth Review | Q37865761 | ||
| Statins, inflammation and kidney disease | Q37883015 | ||
| Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis | Q37925218 | ||
| Coronary Artery Disease in a Large Renal Transplant Population: Implications for Management | Q37932629 | ||
| Heart valve prosthesis selection in patients with end-stage renal disease requiring dialysis: a systematic review and meta-analysis | Q37944612 | ||
| 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q37953802 | ||
| Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis | Q37995151 | ||
| Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant | Q38023320 | ||
| Anticoagulants in atrial fibrillation patients with chronic kidney disease | Q38028855 | ||
| Cardiorenal syndrome: pathophysiology and potential targets for clinical management | Q38068097 | ||
| Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial | Q38500562 | ||
| Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study | Q39599282 | ||
| Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies | Q40303273 | ||
| The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians. | Q40424799 | ||
| A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients | Q40678986 | ||
| Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. | Q40700553 | ||
| Long-term evolution of cardiomyopathy in dialysis patients | Q40832956 | ||
| Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial | Q42821650 | ||
| Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease | Q42830307 | ||
| Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome | Q42911985 | ||
| Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial | Q42912061 | ||
| Sirolimus-eluting stents versus paclitaxel-eluting stents in patients with chronic renal insufficiency | Q43064627 | ||
| Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy | Q43133050 | ||
| Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. | Q43266787 | ||
| Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease | Q43278579 | ||
| Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions | Q43472007 | ||
| The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). | Q43498876 | ||
| Clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents versus bare-metal stents in hemodialysis patients | Q43600517 | ||
| Differential survival after coronary revascularization procedures among patients with renal insufficiency | Q43651251 | ||
| Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. | Q43850038 | ||
| Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure | Q43856223 | ||
| Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency | Q44278953 | ||
| Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial | Q44437779 | ||
| Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing. | Q44545666 | ||
| Safety of low-dose spironolactone administration in chronic haemodialysis patients | Q44613211 | ||
| Is spironolactone safe for dialysis patients? | Q44613215 | ||
| Relation of loop diuretic dose to mortality in advanced heart failure | Q44920477 | ||
| Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes | Q44946730 | ||
| K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease | Q45043772 | ||
| Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients | Q45085892 | ||
| High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination | Q45295887 | ||
| Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study | Q45389074 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| P304 | page(s) | 261-273 | |
| P577 | publication date | 2013-02-19 | |
| P1433 | published in | Nature Reviews Cardiology | Q2108444 |
| P1476 | title | Management of cardiovascular disease in patients with kidney disease | |
| P478 | volume | 10 |
| Q24201456 | Advance care planning for end-stage kidney disease |
| Q26471851 | Advance care planning for end-stage kidney disease |
| Q57914359 | Advanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes and prognostic markers from a large cohort of patients |
| Q44906800 | Chronic kidney disease: How effective and safe are antiplatelet agents in CKD? |
| Q51090162 | Citrate attenuates vascular calcification in chronic renal failure rats |
| Q35088150 | Comparison of heritability of Cystatin C- and creatinine-based estimates of kidney function and their relation to heritability of cardiovascular disease |
| Q38727741 | Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation |
| Q90235968 | Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function |
| Q37314494 | Elevated Neutrophil-to-Lymphocyte Ratio Predicts Intermediate-Term Outcomes in Patients Who Have Advanced Chronic Kidney Disease with Peripheral Artery Disease Receiving Percutaneous Transluminal Angioplasty. |
| Q90366970 | End-stage renal disease is different from chronic kidney disease in upregulating ROS-modulated proinflammatory secretome in PBMCs - A novel multiple-hit model for disease progression |
| Q44826668 | Guidelines for laparoscopic peritoneal dialysis access surgery |
| Q38701617 | Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies |
| Q62632792 | Heart Failure With Preserved Ejection Fraction: Is Ischemia Due to Coronary Microvascular Dysfunction a Mechanistic Factor? |
| Q91850857 | High Cardiovascular Risk Profile in Young Patients on the Kidney Transplant Waiting List |
| Q37696155 | Increased burden of cardiovascular disease in carriers of APOL1 genetic variants |
| Q58565838 | Interrelationship Between Kidney Function and Percutaneous Mitral Valve Interventions: A Comprehensive Review |
| Q90225367 | Klotho: A Major Shareholder in Vascular Aging Enterprises |
| Q57060381 | Large uremic toxins: an unsolved problem in end-stage kidney disease |
| Q87170468 | Lipid-lowering agents in chronic kidney disease: do fibrates have a role? |
| Q37328563 | Nonadherence of Oral Antihyperglycemic Medication Will Increase Risk of End-Stage Renal Disease |
| Q26849298 | Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease |
| Q38159918 | Remote ischaemic conditioning-therapeutic opportunities in renal medicine |
| Q38820488 | Renal dysfunction and transcatheter aortic valve implantation outcomes. |
| Q35097835 | Risk-adjusted analysis of relevant outcome drivers for patients after more than two kidney transplants |
| Q89924903 | Role of direct oral anticoagulants in patients with kidney disease |
| Q96342937 | Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study |
| Q44080629 | The role of fibrates in chronic kidney disease and diabetes mellitus |
| Q89440694 | Ultrasound-guided left lateral transversus abdominis plane block combined with rectus sheath block in peritoneal dialysis catheter placement |
| Q49992231 | Uremic toxins are conditional danger- or homeostasis-associated molecular patterns |
Search more.